Curis Inc CRIS

NAS: CRIS | ISIN: US2312692005   2/06/2023
0,859 USD (+5,01%)
(+5,01%)   2/06/2023

5 mei 2023 · Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

4 mei 2023 · Curis Provides First Quarter 2023 Business Update · Persbericht

27 april 2023 · Curis to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023 · Persbericht

6 april 2023 · Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

3 april 2023 · Curis to Present at Upcoming Healthcare Conferences in April · Persbericht

13 maart 2023 · Curis Provides Fourth Quarter 2022 Business Update · Persbericht

9 maart 2023 · Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call · Persbericht

2 maart 2023 · Curis to Release Fourth Quarter 2022 Financial Results and Hold Conference Call on March 9, 2023 · Persbericht

12 december 2022 · Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS · Persbericht

6 december 2022 · Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia · Persbericht

9 november 2022 · Curis Provides Third Quarter 2022 Business Update · Persbericht

7 november 2022 · Curis Announces Three Presentations at SITC 2022 · Persbericht

2 november 2022 · Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022 · Persbericht

7 oktober 2022 · Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) · Persbericht

3 oktober 2022 · Curis Announces Date for the 1st Symposium on IRAK4 in Cancer · Persbericht

20 september 2022 · Curis Announces Date for the 2nd Annual VISTA Symposium · Persbericht

7 september 2022 · Curis to Present at Upcoming Healthcare Conferences in September · Persbericht

30 augustus 2022 · FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study · Persbericht

18 augustus 2022 · FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib · Persbericht

4 augustus 2022 · Curis Reports Second Quarter 2022 Financial Results and Business Update · Persbericht

Mijn selecties